253 related articles for article (PubMed ID: 36865537)
21. Cutting edge: expression of TNFR2 defines a maximally suppressive subset of mouse CD4+CD25+FoxP3+ T regulatory cells: applicability to tumor-infiltrating T regulatory cells.
Chen X; Subleski JJ; Kopf H; Howard OM; Männel DN; Oppenheim JJ
J Immunol; 2008 May; 180(10):6467-71. PubMed ID: 18453563
[TBL] [Abstract][Full Text] [Related]
22. The Significance of Tumor Necrosis Factor Receptor Type II in CD8
Ye LL; Wei XS; Zhang M; Niu YR; Zhou Q
Front Immunol; 2018; 9():583. PubMed ID: 29623079
[TBL] [Abstract][Full Text] [Related]
23. Antagonistic Antibody Targeting TNFR2 Inhibits Regulatory T Cell Function to Promote Anti-Tumor Activity.
Chen Y; Jia M; Wang S; Xu S; He N
Front Immunol; 2022; 13():835690. PubMed ID: 35251028
[TBL] [Abstract][Full Text] [Related]
24. Regulatory T-cells-related signature for identifying a prognostic subtype of hepatocellular carcinoma with an exhausted tumor microenvironment.
Zhang G
Front Immunol; 2022; 13():975762. PubMed ID: 36189226
[TBL] [Abstract][Full Text] [Related]
25. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
[TBL] [Abstract][Full Text] [Related]
26. Scutellarin enhances anti-tumor immune responses by reducing TNFR2-expressing CD4
Chen S; Li R; Chen Y; Chou CK; Zhang Z; Yang Y; Liao P; Wang Q; Chen X
Biomed Pharmacother; 2022 Jul; 151():113187. PubMed ID: 35676787
[TBL] [Abstract][Full Text] [Related]
27. TNFR2-expressing CD4
He J; Li R; Chen Y; Hu Y; Chen X
Prog Mol Biol Transl Sci; 2019; 164():101-117. PubMed ID: 31383403
[TBL] [Abstract][Full Text] [Related]
28. Immune checkpoint inhibitor resistance in hepatocellular carcinoma.
Wang Z; Wang Y; Gao P; Ding J
Cancer Lett; 2023 Feb; 555():216038. PubMed ID: 36529238
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade.
Genova C; Dellepiane C; Carrega P; Sommariva S; Ferlazzo G; Pronzato P; Gangemi R; Filaci G; Coco S; Croce M
Front Immunol; 2021; 12():799455. PubMed ID: 35069581
[TBL] [Abstract][Full Text] [Related]
30. Tumor PD-L1 and VEGF Expression, and CD8 T Cell Infiltration Predict Clinical Response to Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer.
Nojima Y; Shimizu K; Saisho S; Maeda AI; Kurosaki T; Kurose K; Oga T; Oka M; Nakata M
Anticancer Res; 2021 Nov; 41(11):5469-5475. PubMed ID: 34732416
[TBL] [Abstract][Full Text] [Related]
31. Baseline extracellular vesicle TGF-β is a predictive biomarker for response to immune checkpoint inhibitors and survival in non-small cell lung cancer.
de Miguel-Perez D; Russo A; Gunasekaran M; Buemi F; Hester L; Fan X; Carter-Cooper BA; Lapidus RG; Peleg A; Arroyo-Hernández M; Cardona AF; Naing A; Hirsch FR; Mack PC; Kaushal S; Serrano MJ; Adamo V; Arrieta O; Rolfo C
Cancer; 2023 Feb; 129(4):521-530. PubMed ID: 36484171
[TBL] [Abstract][Full Text] [Related]
32. Characteristics of the immune microenvironment and their clinical significance in non-small cell lung cancer patients with ALK-rearranged mutation.
Zhang B; Zeng J; Zhang H; Zhu S; Wang H; He J; Yang L; Zhou N; Zu L; Xu X; Song Z; Xu S
Front Immunol; 2022; 13():974581. PubMed ID: 36159860
[TBL] [Abstract][Full Text] [Related]
33. Elucidation of the relationships of MET protein expression and gene copy number status with PD-L1 expression and the immune microenvironment in non-small cell lung cancer.
Yoshimura K; Inoue Y; Tsuchiya K; Karayama M; Yamada H; Iwashita Y; Kawase A; Tanahashi M; Ogawa H; Inui N; Funai K; Shinmura K; Niwa H; Suda T; Sugimura H
Lung Cancer; 2020 Mar; 141():21-31. PubMed ID: 31931443
[TBL] [Abstract][Full Text] [Related]
34. Preferential Expression of Programmed Death Ligand 1 Protein in Tumor-Associated Macrophages and Its Potential Role in Immunotherapy for Hepatocellular Carcinoma.
Park DJ; Sung PS; Lee GW; Cho S; Kim SM; Kang BY; Hur W; Yang H; Lee SK; Lee SH; Jung ES; Seo CH; Ahn J; Choi HJ; You YK; Jang JW; Bae SH; Choi JY; Yoon SK
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946835
[TBL] [Abstract][Full Text] [Related]
35. Comparison of Efficacy and Safety of Single and Double Immune Checkpoint Inhibitor-Based First-Line Treatments for Advanced Driver-Gene Wild-Type Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis.
Xu Q; Zhang X; Huang M; Dai X; Gao J; Li S; Sheng L; Huang K; Wang J; Liu L
Front Immunol; 2021; 12():731546. PubMed ID: 34484242
[TBL] [Abstract][Full Text] [Related]
36. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
37. Role of regulatory T cells and checkpoint inhibition in hepatocellular carcinoma.
Langhans B; Nischalke HD; Krämer B; Dold L; Lutz P; Mohr R; Vogt A; Toma M; Eis-Hübinger AM; Nattermann J; Strassburg CP; Gonzalez-Carmona MA; Spengler U
Cancer Immunol Immunother; 2019 Dec; 68(12):2055-2066. PubMed ID: 31724091
[TBL] [Abstract][Full Text] [Related]
38. Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities.
Hack SP; Zhu AX; Wang Y
Front Immunol; 2020; 11():598877. PubMed ID: 33250900
[TBL] [Abstract][Full Text] [Related]
39. TCF1
Koh J; Kim S; Woo YD; Song SG; Yim J; Han B; Lim S; Ahn HK; Mun S; Kim JS; Keam B; Kim YA; Lee SH; Jeon YK; Chung DH
Eur J Cancer; 2022 Oct; 174():10-20. PubMed ID: 35970031
[TBL] [Abstract][Full Text] [Related]
40. Targeting TNFR2, an immune checkpoint stimulator and oncoprotein, is a promising treatment for cancer.
Chen X; Oppenheim JJ
Sci Signal; 2017 Jan; 10(462):. PubMed ID: 28096506
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
